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Abstract
The US Centers for Medicaid and Medicare Services reimburses ambulatory blood pressure 
monitoring (ABPM) for suspected white coat hypertension. We estimated ABPM use between 
2007 and 2010 among a 5% random sample of Medicare beneficiaries (≥ 65 years). In 2007, 2008, 
2009 and 2010, the percentage of beneficiaries with ABPM claims was 0.10%, 0.11%, 0.10%, and 
0.09% respectively. A prior diagnosis of hypertension was more common among those with 
versus without an ABPM claim (77.7% versus 47.0%). Among hypertensive beneficiaries, 95.2% 
of those with an ABPM claim were taking antihypertensive medication. Age 75-84 versus 65-74 
years, having coronary heart disease, chronic kidney disease, multiple prior hypertension 
diagnoses, and having filled multiple classes of antihypertensive medication were associated with 
an increased odds for an ABPM claim among hypertensive beneficiaries. ABPM use was very low 
among Medicare beneficiaries and was not primarily used for diagnosing white coat hypertension 
in untreated individuals.
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Introduction
More than 20 years ago, Pickering et al. introduced the concept of white coat hypertension 
[1]. White coat hypertension is defined as having blood pressure that is elevated when 
measured in the clinic but not elevated when assessed by ambulatory monitoring in 
individuals not taking antihypertensive medications [2]. This is now a well-recognized 
phenomenon, estimated to be present in 15-25% of patients with elevated clinic blood 
pressure [1, 3, 4]. It is generally accepted that the risk of cardiovascular disease events in 
patients with white coat hypertension is relatively low compared to those with both elevated 
clinic and ambulatory blood pressure (i.e., sustained hypertension) [3]. Additionally, the 
benefits of antihypertensive treatment in patients with white coat hypertension have been 
reported to be limited [5].
In 2001, the Centers for Medicaid and Medicare Services (CMS) in the United States (US) 
approved reimbursement for ambulatory blood pressure monitoring (ABPM) when white 
coat hypertension is suspected [6]. In 2011, based on cost-effectiveness data, the National 
Institute for Health and Clinical Excellence (NICE) in the United Kingdom recommended 
that ABPM be performed to confirm the diagnosis of hypertension in individuals presenting 
with clinic hypertension [7]. A recently published 2013 European Society of Hypertension 
Position Paper further emphasized the important role of ABPM in the diagnosis of white 
coat hypertension, as well as in identifying other important blood pressure phenotypes (e.g., 
masked hypertension, nocturnal hypertension, blood pressure variability) [3].
Given the high incidence of clinic hypertension among older adults [8], one would anticipate 
that ABPM use would become common after the reimbursement for suspected white coat 
hypertension was approved by CMS. However, it is not known how frequently ABPM is 
being utilized in older patients in the US. The aim of this study was to estimate national 
rates of ABPM use, time trends, and correlates of use among US Medicare beneficiaries. 
Additionally, we investigated factors associated with the performance of ABPM among 
Medicare beneficiaries with a diagnosis of hypertension.
Methods
Using previously described methods [9, 10], we conducted a study of Medicare beneficiaries 
in the US using the 2006-2010 national 5% random sample from the CMS. Medicare is a US 
federal insurance program that covers individuals 65 years of age and older, on disability, or 
who have end-stage renal disease. Coverage may be chosen on a fee-for-service basis or 
through contracts with managed care organizations (i.e., Medicare Advantage). Specific data 
used for the current analyses include claims from Medicare fee-for-service Parts A (in-
patient), B (out-patient) and D (prescription drug). These data provide Medicare claims, 
whether reimbursed or not, and assessment data linked by beneficiary across the continuum 
of care. We did not include Medicare beneficiaries with coverage through a managed care 
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organization in the current analysis, as claims are incomplete for these individuals. CMS and 
the Institutional Review Board at the University of Alabama at Birmingham approved the 
study.
To examine ABPM utilization and time trends, we created separate yearly cohorts of 
beneficiaries in 2007, 2008, 2009, and 2010. In each calendar year, beneficiaries with an 
ABPM claim in Medicare were identified from outpatient claims that contained Healthcare 
Common Procedure Coding System (HCPCS) codes 93784, 93786, 93788, or 93790 (see 
Supplemental Methods). For beneficiaries with multiple ABPM claims in a calendar year, 
the first ABPM claim of the year was chosen. A beneficiary could be counted in multiple 
calendar years if they had an ABPM claim in more than one year. We refer to the date that 
the ABPM was performed as the “index date.” Beneficiaries without ABPM claims in a 
calendar year were identified and assigned an index date of July 1.
A “look back” period was used to identify antihypertensive medication use and 
comorbidities. The look back period for this analysis included the 365 days prior to, but not 
including, each participant's index date (with January 1, 2006 being the earliest possible date 
in the look back period for our study). Beneficiaries were required to have continuous full 
Medicare coverage (Medicare Parts A, B and D coverage) and to reside in the 50 United 
States or Washington DC for the entire look back period. In order to have the sample 
represent the general population that is eligible for Medicare, we excluded from the analysis 
beneficiaries who were < 65 years of age at the start of the 365-day look back period. 
Additionally, due to concerns about data accuracy, we excluded beneficiaries who were ≥ 
110 years of age on the index date, or who had multiple birth or death dates. A CONSORT 
diagram showing the inclusion/exclusion of US Medicare beneficiaries in our study is 
provided in Supplemental Figure 1.
Covariates
A priori-selected covariates were used to characterize Medicare beneficiaries with ABPM 
claims. Demographics were defined using the Medicare beneficiary enrollment file and 
included age, sex, race/ethnicity, and Medicaid enrollment for the entire look back period (a 
measure of poverty). Comorbid conditions were defined using claims during the look back 
period and previously published algorithms (see Supplemental Methods). These included 
diabetes, coronary heart disease, stroke, and chronic kidney disease [11]. We also 
determined the number of separate days for which each beneficiary had a claim for 
hypertension (outpatient physician evaluation and management claims with ICD-9 diagnosis 
of 401.x - malignant, benign or unspecified essential hypertension). Hypertension was 
defined by outpatient physician evaluation and management claims with ICD-9 diagnosis 
codes of 401.x on 2 or more separate days during the look back period. White coat 
hypertension was defined by one or more inpatient, carrier, or outpatient claims with an 
ICD-9 diagnosis code of 796.2 (i.e. “Elevated blood pressure reading without diagnosis of 
hypertension”) [12]. The number of antihypertensive medication classes each beneficiary 
filled during the look back period was identified from the Medicare Part D file. 
Antihypertensive medication classes were defined using those listed in the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
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(JNC 7) guidelines [11] and were updated, following review by two authors (D.S., S.O.), to 
include new medications.
Statistical Analyses
The percentage of US Medicare beneficiaries with an ABPM claim was calculated for each 
calendar year. We pooled the 2007, 2008, 2009, and 2010 cohorts for the remainder of the 
analyses. For beneficiaries with ABPM claims in multiple calendar years, we used only the 
first year in the pooled analysis. We selected 10 control beneficiaries without ABPM claims 
for each beneficiary with an ABPM claim, matching on the year of the index date.
In the pooled 2007-2010 cohort, we calculated characteristics of Medicare beneficiaries with 
and without ABPM claims. Beneficiary characteristics were calculated first among all 
beneficiaries and then restricted to those with hypertension. As a prior diagnosis of 
hypertension was more common among those beneficiaries with versus without an ABPM 
claim (see Results section below), we calculated the odds ratios for having an ABPM claim 
associated with beneficiary characteristics among those with hypertension, using conditional 
logistic regression from progressively adjusted models. The first model adjusted only for 
age, and a second model included adjustment for age, gender, race/ethnicity, Medicaid buy-
in and comorbidities (diabetes, coronary heart disease, stroke and chronic kidney disease). A 
third model included additional adjustment for the number of claims with hypertension 
diagnoses on separate days during the look back period and the number of antihypertensive 
medication classes filled during the look back period. Finally, we calculated the percentage 
of hypertensive beneficiaries who had white coat hypertension diagnosis codes during the 
look back period, on the ABPM index date, and during the look back period and/or on the 
ABPM index date. Analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC).
Results
Table 1 shows the percentage of beneficiaries in the 5% Medicare sample included in the 
current analysis with and without an ABPM claim by calendar year. For 2007, 2008, 2009 
and 2010, the percentage of Medicare beneficiaries with ABPM claims was 0.10%, 0.11%, 
0.10%, and 0.09% respectively.
Sample Characteristics
Supplemental Table 1 shows the characteristics of Medicare beneficiaries with and without 
an ABPM claim in the 2007-2010 pooled cohort. Individuals with an ABPM claim were 
more likely to have had a diagnosis of hypertension, compared with individuals without an 
ABPM claim (77.7% vs. 47.0%). Individuals with an ABPM claim were also more likely to 
be on antihypertensive medications during the look back period, compared with individuals 
without an ABPM claim (86.9% vs. 69.8%).
Table 2 shows the characteristics of Medicare beneficiaries with and without an ABPM 
claim in the 2007-2010 pooled cohort, restricted to individuals with hypertension. Compared 
to hypertensive individuals without an ABPM claim, those with an ABPM claim were 
significantly more likely to be aged 75 to 84 versus 65 to 74 years of age, white, and to have 
a history of coronary heart disease or chronic kidney disease. In the look back period before 
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the index date, hypertensive individuals with an ABPM claim had more diagnoses of 
hypertension and were more likely to be taking 4 or more classes of antihypertensive 
medication. Also, those with an ABPM claim were significantly less likely to be male, have 
Medicaid buy-in and have diabetes. Of hypertensive individuals with and without an ABPM 
claim, 95.2% and 92.5%, respectively, had filled antihypertensive medications during the 
look-back period.
Correlates of Having an ABPM Claim Among Hypertensive Individuals
Table 3 shows the odds ratios for having an ABPM among hypertensive Medicare 
beneficiaries in the 2007-2010 pooled cohort. Older age, particularly 75 to 84 years, was 
associated with a higher odds ratio of having an ABPM claim. After age adjustment, 
coronary heart disease, chronic kidney disease, more diagnoses of hypertension, and filling 
more classes of antihypertensive medication were each associated with significantly 
increased odds ratios for having an ABPM claim. In addition, after age-adjustment, males, 
Blacks, Hispanics, and Asians versus whites, and those with Medicaid buy-in and diabetes 
were significantly less likely to have an ABPM claim. These associations were similar after 
demographic and medical co-morbidity adjustment, and after full multivariable adjustment.
White Coat Hypertension and ABPM
Figure 1 shows the percentage of individuals with diagnoses of white coat hypertension 
(ICD-9 diagnosis code of 796.2) among hypertensive Medicare beneficiaries with and 
without ABPM claims. Medicare beneficiaries with an ABPM claim were more likely than 
their counterparts without an ABPM claim to have a white coat hypertension diagnosis in 
the look back period before the index date (8.2% versus 2.2%), on the index date (58.3% 
versus 0.0%), or in the look back period before the index date and/or on the index date 
(60.1% versus 2.2%).
Discussion
There are several principal findings of our study. First, the percentage of US Medicare 
beneficiaries with ABPM claims was very low and did not change from 2007 through 2010. 
Second, individuals with an ABPM claim were more likely to have medical comorbidities 
including coronary heart disease, stroke, and chronic kidney disease, more hypertension 
diagnoses, and filled 4 or more classes of antihypertensive medications. Third, although a 
diagnosis of white coat hypertension was more common in hypertensive individuals with an 
ABPM claim versus individuals without an ABPM claim, only 60.1% of individuals with an 
ABPM claim had a white coat hypertension diagnosis. Further, 86.9% of Medicare 
beneficiaries with an ABPM claim, and 95.2% of hypertensive Medicare beneficiaries with 
an ABPM claim were taking antihypertensive medications.
In the US, suspected white coat hypertension is the only CMS-reimbursable indication for 
ABPM [6]. International hypertension guidelines [7, 13] and a recent position paper [3] 
support the role of ABPM in the diagnosis of white coat hypertension. Both the 2011 NICE 
guidelines in the United Kingdom [7] and a 2013 European Society of Hypertension position 
paper [3] recommend ABPM for the exclusion or confirmation of white coat hypertension. 
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A 2008 American Society of Hypertension Position Paper [14] also indicated that out-of-
office blood pressure measurement including ABPM is important for detecting white coat 
hypertension. The prevalence of white coat hypertension is estimated to be 15-25% among 
patients with elevated clinic blood pressure [1, 3, 4]. The risk of white coat hypertension 
increases with age, with the highest prevalence among the elderly [3, 15]. In this study of 
Medicare beneficiaries, claims for ABPM were rare, suggesting that ABPM has not reached 
a sufficient level of utilization or acceptance for older patients in the US.
As part of a 2005 Scientific Statement from the American Heart Association Council on 
High Blood Pressure Research, Pickering et al. [4] recommended that the primary purpose 
of ABPM was for confirming the diagnosis of hypertension and excluding white coat 
hypertension in untreated individuals. However, our data suggest that in Medicare 
beneficiaries, the primary indication for ABPM was not for the diagnosis of white coat 
hypertension in untreated individuals. ABPM is also indicated for monitoring out-of-clinic 
blood pressure in individuals taking antihypertensive medication [3]. Evidence suggests that 
ABPM provides a better assessment of the blood pressure response to treatment than 
readings measured in the clinic [3]. ABPM can provide an assessment of the effects of 
antihypertensive medications on average ambulatory blood pressure as well as the diurnal 
pattern of blood pressure over a 24-hour period [3]. In our study, an ABPM claim was more 
likely in hypertensive individuals with several medical comorbidities and those who were 
taking multiple antihypertensive medications. This suggests that from 2007 to 2010, ABPM 
was primarily utilized for the management of treated hypertension in Medicare beneficiaries.
A substantial proportion of patients require antihypertensive medications from three or more 
classes in order to achieve blood pressure control. In 2008, the American Heart Association 
(AHA) published a scientific statement [16] on a sub-class of hypertensive patients 
considered to have treatment-resistant hypertension, defined as having uncontrolled blood 
pressure despite the use of antihypertensive medications from three or more classes, or the 
use of four or more antihypertensive medication classes to achieve blood pressure control. 
ABPM is currently recommended for the evaluation of patients with treatment-resistant 
hypertension [3], as it can determine which patients have white coat resistant hypertension 
[17, 18]. In adjusted models, having more hypertension diagnoses and filling multiple 
(particularly 4 or more) classes of antihypertensive medication were associated with a 
significantly higher likelihood of having an ABPM claim. Further, 60.1% of hypertensive 
individuals with an ABPM claim, the vast majority of whom were on antihypertensive 
medications, had a diagnosis of white coat hypertension. These findings suggest that in 
Medicare beneficiaries, ABPM was performed disproportionally to assess for white coat 
resistant hypertension. Treatment-resistant hypertension is not a reimbursable condition for 
ABPM in Medicare. However, as we show in an accompanying manuscript (see Kent et al. 
JASH manuscript), no differences in the proportion of ABPM claims that are reimbursed 
were present by number of antihypertensive medication classes a beneficiary was taking.
The reasons for the low utilization of ABPM in Medicare beneficiaries, particularly for 
suspected white coat hypertension are unknown. There are several practical issues that may 
limit the wider spread use of ABPM in the medical setting in the US. First, the Medicare 
physician fee, which is typically $50-60 (see accompanying Kent et al. JASH manuscript), is 
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less than the true cost of the device and the conduct of ABPM, dis-incentivizing practicing 
clinicians. Second, ABPM is not widely available in primary care settings in the US, and is 
generally offered by specialized centers focused primarily on hypertension or cardiovascular 
medicine. Although the American Society of Hypertension has had an initiative for the 
recognition of Specialized Hypertension Centers [19], the number of these centers is small 
[20] and likely to be inaccessible to many clinics and hospitals in the US due to different 
geographic locations and competing healthcare systems. Third, primary care physicians may 
seek to have their own ABPM services, but the lack of formal training or certification in the 
US may make it more difficult for physicians set up these services in their practices. These 
issues likely contribute to the low utilization of ABPM in Medicare beneficiaries.
The major strength of the study is that Medicare provides longitudinal data that are highly 
generalizable to older adults in the US. With these data, we were able to assess the use of, 
and secular national trends of ABPM utilization for Medicare beneficiaries over a 4-year 
period. Scarce data are available on the utilization, time trends, and correlates of ABPM use 
in the US. Identifying these estimates is vital given the important role that ABPM can have 
in the diagnosis and treatment of hypertension.
Several limitations must be noted when interpreting our findings. Our analysis was limited 
to individuals who were aged 65 years and older. Whether our findings are generalizable to 
younger individuals is unknown. Further, as with all claims-based analyses, our results 
depend on the accuracy of coding to measure disease states and pharmacy fills. While the 
ICD-9 codes for diabetes, coronary heart disease, and stroke have high positive predictive 
values, the codes for identifying chronic kidney disease in Medicare do not [21-23]. In 
addition, given the low reimbursement for ABPM by Medicare, some physicians may not 
have submitted claims for reimbursement. Finally, our findings may not be generalizable to 
claims submitted to private insurance carriers. However, because the coverage of ABPM by 
private insurance carriers [3] is not markedly higher than what is covered by Medicare, it is 
unlikely that our estimates of ABPM claims are substantially different.
Given the most recently published European Society of Hypertension position paper [3] and 
NICE United Kingdom guidelines [7], and emerging data on the prognostic value of masked 
hypertension [24], nocturnal hypertension [25], and blood pressure variability [26], the use 
of ABPM may become more routine, particularly in European countries. The current study 
suggests that in the US, ABPM is far from being the standard of care for Medicare 
beneficiaries. These data also show that ABPM is not being used primarily for the diagnosis 
of white coat hypertension in untreated individuals. Given that the risk for cardiovascular 
disease is substantially lower among patients with white coat versus sustained hypertension 
and that the benefits of treatment of white coat hypertension are limited, this is a missed 
opportunity to provide high quality evidence-based care to patients who may be 
inappropriately treated with antihypertensive medications.
Substantial evidence has accumulated supporting the diagnostic and prognostic value of 
ABPM. Data from the current study highlight the need for efforts to educate clinicians in the 
US about the value of ABPM as a clinical tool to confirm the diagnosis of hypertension and 
guide decisions on antihypertensive medications titration in patients receiving treatment. 
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Given the very low use of ABPM observed in the current study, the identification of barriers 
to its successful implementation in clinical practice in the US warrants future study.
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Refer to Web version on PubMed Central for supplementary material.
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• ABPM use was very low among Medicare beneficiaries.
• A prior hypertension diagnosis was more common among those with an ABPM 
claim.
• Most hypertensives with an ABPM claim were taking antihypertensive 
medication.
• Among hypertensives with an ABPM claim, 60.1% had a white coat 
hypertension code.
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Figure 1. Beneficiaries in the 5% Medicare 2007-2010 sample with claims containing a white 
coat hypertension (WCH) diagnosis code, among those with (black bars) and without (hashed 
bars) an ambulatory blood pressure monitoring (ABPM) claim
The index date for those with an ABPM claim is the ABPM claim date. The index date for 
those without an ABPM claim is July 1 of the year the beneficiary was matched to a 
beneficiary with an ABPM claim.
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Table 1
Beneficiaries in the 5% Medicare sample with and without an ambulatory blood pressure monitoring (ABPM) 
claim, by year
Year
ABPM Claim Status 2007 2008 2009 2010
No ABPM claim, n (%) 508,885 (99.90%) 534,471 (99.89%) 537,231 (99.90%) 544,337 (99.91%)
Has ABPM claim, n (%) 498 (0.10%) 562 (0.11%) 532 (0.10%) 506 (0.09%)
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Table 2
Characteristics of hypertensive Medicare beneficiaries in the 5% Medicare sample with and without an 
ambulatory blood pressure monitoring (ABPM) claim from 2007-2010
ABPM claim
Characteristics Yes (n=1,532) No (n=9,273) P value*
Age, years <0.001
    65 to 74 660 (43.1%) 5406 (58.3%)
    75 to 84 660 (43.1%) 2564 (27.7%)
    85 and above 212 (13.8%) 1303 (14.1%)
Male 452 (29.5%) 3309 (35.7%) <0.001
Race/ethnicity <0.001
    White 1349 (88.1%) 7484 (80.7%)
    Black 96 (6.3%) 1041 (11.2%)
    Hispanic 32 (2.1%) 286 (3.1%)
    Asian 30 (2.0%) 252 (2.7%)
    Other 25 (1.6%) 210 (2.3%)
Medicaid buy-in† 270 (17.6%) 2225 (24.0%) <0.001
Diabetes† 437 (28.5%) 3035 (32.7%) 0.001
Coronary heart disease† 693 (45.2%) 3179 (34.3%) <0.001
Stroke† 96 (6.3%) 552 (6.0%) 0.632
Chronic kidney disease† 301 (19.6%) 1119 (12.1%) <0.001
Number of hypertension diagnoses† <0.001
    2 234 (15.3%) 2556 (27.6%)
    3 221 (14.4%) 2050 (22.1%)
    4 222 (14.5%) 1511 (16.3%)
    5 179 (11.7%) 950 (10.2%)
    6 or more 676 (44.1%) 2206 (23.8%)
Number of antihypertensive medications† <0.001
    0 73 (4.8%) 699 (7.5%)
    1 205 (13.4%) 1918 (20.7%)
    2 350 (22.8%) 2673 (28.8%)
    3 378 (24.7%) 2245 (24.2%)
    4 or more 526 (34.3%) 1738 (18.7%)
Data in the table are expressed as number (%).
*
P-values are obtained using chi-squared tests.
†Variables determined from the period before the beneficiaries index date are defined using the 365 days before, and not including the index date.
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Table 3
Odds ratio for having an ambulatory blood pressure monitoring claim among hypertensive beneficiaries in the 
pooled 2007-2010 5% Medicare sample (n=10,805)
Odds Ratio (95% CI)
Characteristics Age-adjusted Demographic and comorbidity-adjusted* Fully adjusted†
Age, years
    65 to 74 Ref Ref Ref
    75 to 84 2.19 (1.95 2.47) 1.96 (1.73 2.21) 1.83 (1.62 2.08)
    85 and above 1.38 (1.17 1.63) 1.11 (0.94 1.32) 1.00 (0.84 1.19)
Male 0.79 (0.70 0.89) 0.71 (0.62 0.80) 0.78 (0.69 0.89)
Race/ethnicity
    White Ref Ref Ref
    Black 0.54 (0.43 0.67) 0.56 (0.45 0.71) 0.49 (0.39 0.61)
    Hispanic 0.58 (0.40 0.85) 0.70 (0.47 1.02) 0.66 (0.45 0.98)
    Asian 0.64 (0.44 0.94) 0.79 (0.53 1.17) 0.82 (0.54 1.22)
    Other 0.68 (0.45 1.04) 0.79 (0.52 1.21) 0.84 (0.55 1.30)
Medicaid buy-in‡ 0.69 (0.60 0.80) 0.75 (0.64 0.87) 0.68 (0.58 0.79)
Diabetes‡ 0.84 (0.74 0.95) 0.81 (0.71 0.91) 0.72 (0.63 0.82)
Coronary heart disease‡ 1.51 (1.35 1.69) 1.53 (1.37 1.72) 1.28 (1.13 1.44)
Stroke‡ 0.98 (0.78 1.23) 0.97 (0.77 1.22) 0.88 (0.70 1.11)
Chronic kidney disease‡ 1.70 (1.47 1.96) 1.77 (1.53 2.06) 1.35 (1.15 1.57)
Number of hypertension diagnoses‡
    2 Ref Ref Ref
    3 1.17 (0.96 1.41) 1.18 (0.97 1.43) 1.14 (0.93 1.38)
    4 1.57 (1.29 1.90) 1.60 (1.32 1.95) 1.51 (1.24 1.84)
    5 2.03 (1.65 2.50) 2.06 (1.67 2.55) 1.91 (1.54 2.37)
    6 or more 3.17 (2.70 3.73) 3.23 (2.73 3.81) 2.82 (2.38 3.33)
Number of antihypertensive medications‡
    0 Ref Ref Ref
    1 1.05 (0.79 1.39) 1.05 (0.79 1.39) 1.02 (0.76 1.35)
    2 1.28 (0.98 1.67) 1.27 (0.97 1.66) 1.18 (0.90 1.54)
    3 1.62 (1.24 2.11) 1.58 (1.21 2.06) 1.37 (1.04 1.79)
    4 or more 2.89 (2.22 3.75) 2.79 (2.13 3.64) 2.22 (1.69 2.91)
*
Model adjusts for age, sex, race/ethnicity, Medicaid buy-in, diabetes, coronary heart disease, stroke, and chronic kidney disease.
†
Fully-adjusted model includes all characteristics in the same model.
‡Variables determined from the period before the beneficiaries index date are defined using the 365 days before, and not including the index date.
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